Stockreport

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Perspective Therapeutics, Inc.  (CATX) 
PDF Updated interim results from the Company’s [212Pb]VMT-a-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presente [Read more]